KeViRx Revenue and Competitors
Employee Data
- KeViRx has 5 Employees.
- KeViRx grew their employee count by 25% last year.
KeViRx's People
| Name | Title | Email/Phone |
|---|
KeViRx Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.4M | 7 | -22% | N/A | N/A |
#2 | $4.3M | 28 | 4% | N/A | N/A |
#3 | $1.1M | 7 | 0% | N/A | N/A |
#4 | $3.5M | 45 | -52% | $56.5M | N/A |
#5 | $0.3M | 2 | 0% | N/A | N/A |
#6 | $4.5M | 29 | 21% | N/A | N/A |
#7 | $1.9M | 12 | 9% | N/A | N/A |
#8 | $7M | 45 | 5% | N/A | N/A |
#9 | $6.7M | 43 | 5% | N/A | N/A |
#10 | $2M | 13 | -13% | N/A | N/A |
What Is KeViRx?
KeViRx, Inc. is a preclinical stage pharmaceutical company headquartered in Charlottesville, VA. We are developing small molecules drugs that treat microvascular leakage and inflammation, pathologies that are the basis for many diseases, including cancer and respiratory disease. We are now entering IND-enabling studies for pulmonary microvascular leakage and inflammation during acute lung injury. \n\nOur lead asset, KVX-053 has potent anti-inflammatory and immunomodulatory effects. In preclinical models, KVX-053 reduces lung injury scoring & the biomarkers of lung injury, inflammation & proinflammatory cytokine release, & immune cell infiltration into the lung. KVX-053 also improves lung function after lung injury.\n\nContact us for more information at info@KeViRx.com.
keywords:N/A
N/A
Total Funding
5
Number of Employees
N/A
Revenue (est)
25%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Charlottesville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.4M | 5 | 0% | N/A |
#2 | $0.8M | 5 | -29% | N/A |
#3 | N/A | 5 | -17% | N/A |
#4 | $0.4M | 5 | 0% | N/A |
#5 | N/A | 6 | 0% | N/A |